{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:05:20Z","timestamp":1765609520519,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.rpsm.2012.03.006","type":"journal-article","created":{"date-parts":[[2012,6,30]],"date-time":"2012-06-30T13:45:14Z","timestamp":1341063914000},"page":"217-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efectos secundarios del tratamiento antipsic\u00f3tico en ni\u00f1os y adolescentes na\u00efve o quasi-na\u00efve: dise\u00f1o de un protocolo de seguimiento y resultados basales"],"prefix":"10.1016","volume":"5","author":[{"given":"Jessica","family":"Merch\u00e1n-Naranjo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concha","family":"Bail\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Baeza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Calvo-Escalona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Morer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Mart\u00ednez-Cantarero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia Andr\u00e9s","family":"Nestares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Alda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpsm.2012.03.006_bib0005","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archpedi.158.8.753","article-title":"New users of antipsychotic medications among children enrolled in TennCare","volume":"158","author":"Cooper","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0010","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotic drugs","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0015","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.euroneuro.2011.04.001","article-title":"Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies","volume":"21","author":"Zuddas","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","article-title":"Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons","volume":"21","author":"Fraguas","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.rpsm.2010.08.001","article-title":"Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents","volume":"3","author":"Fraguas","year":"2010","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0030","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/cap.2006.0039","article-title":"Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents","volume":"17","author":"Laita","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0035","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.chi.0000157543.74509.c8","article-title":"Trends in the use of typical and atypical antipsychotics in children and adolescents","volume":"44","author":"Patel","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl. 4","key":"10.1016\/j.rpsm.2012.03.006_bib0040","doi-asserted-by":"crossref","first-page":"S471","DOI":"10.1016\/j.euroneuro.2004.08.006","article-title":"Clinical effectiveness of new generation antipsychotics in adolescent patients","volume":"14","author":"Arango","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 7","key":"10.1016\/j.rpsm.2012.03.006_bib0045","first-page":"29","article-title":"Use of antipsychotics in children and adolescents","volume":"66","author":"Findling","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0050","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","article-title":"Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns","volume":"19","author":"Vitiello","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1176\/ps.2010.61.2.123","article-title":"Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005","volume":"61","author":"Pathak","year":"2010","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0060","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1542\/peds.2007-2008","article-title":"Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom","volume":"121","author":"Rani","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0065","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1176\/ps.2008.59.5.554","article-title":"Use of antipsychotic drugs among Dutch youths between 1997 and 2005","volume":"59","author":"Kalverdijk","year":"2008","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0070","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study","volume":"165","author":"Sikich","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","article-title":"Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes","volume":"47","author":"Correll","year":"2008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0080","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.4088\/JCP.v69n0717","article-title":"Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics","volume":"69","author":"Fraguas","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0085","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(08)61765-1","article-title":"The spurious advance of antipsychotic drug therapy","volume":"373","author":"Tyrer","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.10.022","article-title":"Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population","volume":"99","author":"Perez-Iglesias","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0095","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00787-009-0749-5","article-title":"Olanzapine compared to quetiapine in adolescents with a first psychotic episode","volume":"18","author":"Arango","year":"2009","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.rpsm.2012.03.006_bib0100","first-page":"29","article-title":"C A. Metabolic side effects in antipsychotic-na\u00efve adolescents after 12 months of treatment with second-generation antipsychotics","volume":"37","author":"Pina","year":"2011","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","article-title":"Which comes first: atypical antipsychotic treatment or cardiometabolic risk?","volume":"119","author":"Stahl","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0110","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1399-5618.2010.00797.x","article-title":"Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses","volume":"12","author":"Moreno","year":"2010","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0115","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"year":"1994","series-title":"Diagnostic and statistical manual of mental disorders","key":"10.1016\/j.rpsm.2012.03.006_bib0120"},{"year":"2004","series-title":"Curvas y tablas de crecimiento: estudios longitudinal y transversal","author":"Sobradillo","key":"10.1016\/j.rpsm.2012.03.006_bib0125"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0130","series-title":"Criterios para la prevenci\u00f3n de la obesidad infantil y juvenil. Documento de consenso del grupo colaborativo AEP-SENC-SEEDO. Dossier de consenso","article-title":"Curvas de referencia para la tipificaci\u00f3n ponderal","author":"Serra","year":"2002"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0135","doi-asserted-by":"crossref","unstructured":"National highblood pressure education Program working group on high blood pressure in children and adolescents. The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-576.","DOI":"10.1542\/peds.114.2.S2.555"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0145","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/adc.44.235.291","article-title":"Variations in pattern of pubertal changes in girls","volume":"44","author":"Marshall","year":"1969","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/adc.45.239.13","article-title":"Variations in the pattern of pubertal changes in boys","volume":"45","author":"Marshall","year":"1970","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-1781(97)03031-X","article-title":"The Maryland Psychiatric Research Center scale and the characterization of involuntary movements","volume":"70","author":"Cassady","year":"1997","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0165","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.schbul.a006912","article-title":"Combination antipsychotics: pros, cons, and questions","volume":"28","author":"Miller","year":"2002","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0170","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/0929867043456070","article-title":"A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation","volume":"11","author":"Stahl","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0175","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4088\/JCP.v68n1115","article-title":"The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update","volume":"68","author":"Moore","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0180","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"Simon","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/104454602760219126","article-title":"Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine","volume":"12","author":"Alfaro","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0190","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":"A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia","volume":"19","author":"Haas","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0195","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.euroneuro.2009.04.003","article-title":"Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice","volume":"19","author":"Goodwin","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0200","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/cap.2007.0123","article-title":"A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders","volume":"18","author":"Jensen","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0205","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","article-title":"Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents","volume":"45","author":"Correll","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0210","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1399-5618.2010.00798.x","article-title":"Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials","volume":"12","author":"Correll","year":"2010","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.rpsm.2012.03.006_bib0215","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1399-5618.2010.00796.x","article-title":"Primum non nocere: balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder","volume":"12","author":"DelBello","year":"2010","journal-title":"Bipolar Disord"}],"container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989112000948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989112000948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:26:04Z","timestamp":1761823564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1888989112000948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1888989112000948"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2012.03.006","relation":{},"ISSN":["1888-9891"],"issn-type":[{"type":"print","value":"1888-9891"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectos secundarios del tratamiento antipsic\u00f3tico en ni\u00f1os y adolescentes na\u00efve o quasi-na\u00efve: dise\u00f1o de un protocolo de seguimiento y resultados basales","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda  y Salud Mental","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2012.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 SEP y SEPB. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}